

The Onset of In-Vivo Dehydration in Gas -Based Intraperitoneal Hyperthermia and Its Cytotoxic Effects on Colon Cancer Cells

Agata Diakun¹, Tanja Khosrawipour^{2,3*}, Agata Mikolajczyk-Martinez⁴, Jakub Nicpoń⁵, Zdzisław Kiełbowicz⁵, Przemysław Prządka⁵, Bartłomiej Liszka⁵, Wojciech Kielan¹, Kacper Zielinski⁶, Pawel Migdal⁷, Hien Lau⁸, Shiri Li⁹ and Veria Khosrawipour^{4,10}

¹ 2nd Department of General Surgery and Surgical Oncology, Wroclaw Medical University, Wroclaw, Poland,
² Department of Surgery (A), University-Hospital Düsseldorf, Düsseldorf, Germany, ³ Medical faculty, Heinrich-Heine
University, Düsseldorf, Germany, ⁴ Department of Biochemistry and Molecular Biology, Faculty of Veterinary Sciences,
Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland, ⁶ Department of Surgery, Faculty of Veterinary
Sciences, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland, ⁶ Department of Anesthesiology,
Wroclaw Medical University, Wroclaw, Poland, ⁷ Department of Environment, Hygiene and Animal Welfare, University of
Environmental and Life Sciences, Wroclaw, Poland, ⁸ Department of Surgery, University of California, Irvine, Irvine, CA, United
States, ⁹ Division of Colon and Rectal Surgery, Department of Surgery, New York Presbyterian Hospital- Weill Cornell College
of Medicine, New York, NY, United States, ¹⁰ Department of Surgery, Petrus-Hospital Wuppertal, Germany

Background: Peritoneal metastasis (PM) is an ongoing challenge in surgical oncology. Current therapeutic options, including intravenous and intraperitoneal (i.p.) chemotherapies display limited clinical efficacy, resulting in an overall poor prognosis in affected patients. Combined hyperthermia and dehydration induced by a high-flow, gasbased i.p. hyperthermic procedure could be a novel approach in PM treatment. Our study is the first to evaluate the therapeutic potential of i.p. dehydration, hyperthermia, as well as the combination of both mechanisms in an *in-vivo* setting.

Methods: For this study, three swine were subjected to diagnostic laparoscopy under a high-flow air stream at 48°, 49° and 50°Celsius (C). Hygrometry of the in- and outflow airstream was measured to calculate surface evaporation and i.p. dehydration. To analyze the effects of this concept, *in vitro* colon cancer cells (HT-29) were treated with hyperthermia and dehydration. Cytotoxicity and cell viability were measured at different time intervals. Additionally, structural changes of dehydrated cells were analyzed using scanning electron microscopy.

Results: According to our results, both dehydration and hyperthermia were cytotoxic to HT-29 cells. However, while dehydration reduced cell viability, hyperthermia did not. However, dehydration effects on cell viability were significantly increased when combined with hyperthermia (p<0.01).

OPEN ACCESS

Edited by:

Rehan Khan, Institute of Nano Science and Technology (INST), India

Reviewed by:

Rakesh Garg, All India Institute of Medical Sciences, India Natale Calomino, University of Siena, Italy

> *Correspondence: Tanja Khosrawipour tkhosrawipour@gmail.com

Specialty section:

This article was submitted to Surgical Oncology, a section of the journal Frontiers in Oncology

Received: 24 April 2022 **Accepted:** 23 May 2022 **Published:** 29 June 2022

Citation:

Diakun A, Khosrawipour T, Mikolajczyk-Martinez A, Nicpoń J, Kiełbowicz Z, Prządka P, Liszka B, Kielan W, Zielinski K, Migdal P, Lau H, Li S and Khosrawipour V (2022) The Onset of In-Vivo Dehydration in Gas -Based Intraperitoneal Hyperthermia and Its Cytotoxic Effects on Colon Cancer Cells. Front. Oncol. 12:927714. doi: 10.3389/fonc.2022.927714

June 2022 | Volume 12 | Article 927714

1

Conclusions: Changes to the physiological milieu of the peritoneal cavity could significantly reduce PM. Therefore, limited dehydration of the abdominal cavity might be a feasible, additional tool in PM treatment. Further studies are required to investigate dehydration effects and their applicability in PM management.

Keywords: dehydration, colorectal cancer, peritoneal metastasis (PM), hyperthermia, electron microscopy

INTRODUCTION

While peritoneal metastasis (PM) is a common manifestation of advanced gastrointestinal and gynecological cancers, it remains a challenge to surgical oncology with an overall poor prognosis. Statistically, affected patients do not survive the first year after diagnosis due to rapid tumor progression in the abdominal cavity and subsequent complications (1, 2). In recent years, various attempts have been made to develop new strategies for PM management. Despite these efforts, there have not been any significant scientific developments that ensure long-term clinical improvement.

In fact, one of the main shortcomings observed with current therapies include limited therapeutic effects observed with systemic chemotherapy. This can be attributed to systemic drug loss and subtherapeutic drug concentrations in the peritoneum (3, 4). As a result, locoregional concepts e.g. intraperitoneal (i.p.) chemotherapy have been introduced to further improve local drug availability. However, later studies uncovered that i.p. chemotherapies also display limited clinical efficacy (5). Currently, the combination of cytoreductive surgery (CRS) with fluid based hyperthermic intraperitoneal chemotherapy (HIPEC), offers hope for a curative outcome in patients with limited disease. CRS and HIPEC is gaining more popularity in the field of surgery, as clinical trials describe advantageous results in highly selective patients (6, 7). Despite this encouraging data, it is important to note that only patients suffering from limited diseases and without visible peritoneal seeding following CRS are considered to benefit from this therapeutic option (8, 9). For patients with extensive PM who do not qualify for CRS and HIPEC, the option of pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been introduced to the clinical setting (10, 11). In PIPAC, a fluid chemosolution is aerosolized and injected into the abdominal cavity covering the abdominal compartment. In fact, PIPAC has shown some positive results (12, 13) and several attempts have been made to improve (14, 15) and extend (16) its application. Nevertheless, the use of PIPAC in the clinical setting does not seem to fundamentally change patient outcome.

Many patients without distant metastasis often display the clinical picture of metastatic seeding in the peritoneal cavity. PM cells are often either confined to the peritoneum or minimally infiltrate local and peritoneal tissues (17, 18). It is suggested that peritoneal seeding is enhanced due to facilitated movement of floating cancer cells within the peritoneum (19, 20). The presence of disseminated cancer cells has been associated with a higher recurrence rate and a poorer survival (21). Using the peritoneal milieu as a favorable habitat for growth, adherent

cancer cells can further infiltrate and permeate into tissues (22, 23). Additionally, the glucose and protein-rich cavitary fluid can further enhance this effect. In fact, the abdominal cavity offers optimal growth potential for local malignant tumor cells. Consequently, we assume that changing the biology of this compartment could lead the way to optimized therapies. Thus, it is necessary to investigate whether changing the biological properties of the peritoneum could be a feasible option to delay or even halt PM progression.

The application of dehydration combined with hyperthermia could be an innovative approach to alter the biological properties of this compartment. Malignant tumor cell progression could be terminated in a less hospitable environment. Our study is in strong contrast to previous attempts, which all included the use of chemotherapeutic applications. By means of this study, we aim to calculate the extent of evaporation and dehydration that may occur during laparoscopy. Finally, using an *in-vivo* swine model, we examine whether dehydration can be achieved by the proposed laparoscopic system as well as analyze the sensitivity of colon cancer cells to hyperthermia and dehydration at different levels of exposure.

MATERIAL AND METHODS

In-Vivo Swine Model

For the *in-vivo* part of this study, three 65-day-old swine (Polish white flod) were used. The swine received diagnostic laparoscopy without any additionally surgical intervention. Laparoscopy was performed under a high-flow air stream of 15 liters per minute (1/ min). The swine used were part of a larger study on hyperthermia and dehydration. The inflowing air temperature for the swine were 48°, 49 and 50°Celsius (C), respectively. Intracavitary temperatures were monitored to detect the onset of critical intraabdominal heating. All animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals as published by the National Institutes of Health. The swine were premedicated with an intramuscular injection of midazolam (0.3 mg/kg, WZF Polfa S.A., Poland), medetomidine (0.02 mg/kg, Cepetor 1 mg/ml, CP-Pharma Handelsgesellschaft, Germany) and ketamine (9 mg/kg, Ketamina 100 mg/ml, Biowet Puławy sp. z o.o., Poland) mixture. Analgesia was performed with Propofol at 1mg/kg. Swine were intubated and further anesthesia was continued with isoflurane 1%. Additional analgesia was provided with fentanyl 2µg/kg and crystalloid fluid at 0.2 - 0.3 µg/kg/min. The swine were placed in a supine position. An infra-umbilical mini laparotomy was performed and another one at about 8 cm

distance to the first one. A 10 mm trocar (Kii[®]Balloon Blunt Tip System, Applied Medical, Rancho Santa Margarita, CA, USA) was inserted through the infra-umbilical trocar while multiple 5 mm trocars were placed at the other sites (**Figure 1A**) after insufflation. The abdominal cavity was insufflated with filtered room air *via* a tube entering the central 10 mm trocar. An initial diagnostic check-up was conducted *via* laparoscopic imaging using a 5 mm camera system (Karl Storz 5mm/30° Laparoscope/ Tuttlingen, Germany) through a 5 mm trocar. After visual confirmation and placement of multiple temperature sensors (**Figure 1B**), the high-flow air stream was turned on at 15 l/min for a total of 45 minutes. Humidity levels at the in- and outflow was measured.

Creating an Operative Model for Laparoscopic Dehydration of the Abdominal Cavity

The operative model for dehydration assumes a 4 Liter ($V_B = 4$ L) abdominal capnoperitoneum, which corresponds to an average sized capnoperitoneum observed during laparoscopy. Humidity levels of in- and outflowing air were measured. Based on the mean humidity difference, the amount of removed water from the abdominal cavity was calculated. The saturation pressure of room air is 7297 Pascal and the maximum density of water vapor at 40°C is 0.051 kg/m³. At a constant flow of 15 l/min, a model for a time dependent removal rate was calculated.

Cell Cultures

The human colorectal cancer cell lines HT-29 were purchased from the CLS (Cell Lines Service GmbH, Eppelheim, Germany). Cells were then grown in Dulbecco's modified Eagle's medium (DMEM - high glucose, Sigma-Aldrich, Poznan, Poland). The following supplements were added to the medium: 10% heatinactivated fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Poland), 2 mmol/L glutamine, 100 IU/mL penicillin, and 100 μ g/mL streptomycin (Sigma-Aldrich). Cells were then incubated in a humidified 5% CO₂ incubator (NuAire CO₂ Incubator, Biogenet, Warszawa, Poland) at 37°C. Afterwards, 1.4 x 10⁵ cells per well were seeded in 24-well plates (TC Plate 24 Well, Standard, F, Sarstedt AG & Co. KG, Germany) and incubated for 48 hours. Cells subjected to electron microscopy (EM) analysis were seeded on sterile glasscovers.

In Vitro Cell Dehydration

Cells were divided into three main groups and exposed to 37°, 45° and 48°C for 30 minutes. Each group was separately exposed to different durations of dehydration (0, 5, 10, 20, 25 and 30 minutes) (at 85% percent humidity) in the cell incubator. After 0 and 20 minutes of dehydration, cells that were seeded on sterile glasscovers were subjected to cellular analyses using scanning electron microscopy (SEM).

Cytotoxicity Assay

To obtain maximum LDH activity, cell lysis reagent was added into each well following exposure to hyperthermia and dehydration and incubated at 37°C for 45 minutes. Spontaneous LDH activity was assessed for each group. Wells were incubated in darkness and at room temperature for 30 minutes, then a stop reagent solution was added and absorbance was measured at 490nm on a microplate reader (Tecan, Basel, Switzerland). Percentage of cytotoxicity was calculated using the following formula:





% cytotoxicity = (compound-treated LDH activity – spontaneous LDH activity) ÷ (Maximum LDH activity – Spontaneous LDH activity) x 100%.

MTS-Testing on Cell Viability

Cell proliferation was determined *via* colorimetric CellTiter 96[®] AQueous One Solution assay (Promega, Poland) 24 hours after hyperthermia and dehydration exposure. The test was performed with our modifications according to the manufacturer's instructions. Briefly, medium was removed from each well and replaced by 0.3 mL of fresh DMEM. Next, following one hour of incubation at 37°C at 5% CO₂, an MTS-based reagent was added to each well and absorbance at 490nm was measured using a microplate reader (Tecan, Basel, Switzerland). The percentage of proliferation was regulated for all groups using untreated cells as control.

Electron Microscopy to Determine Cell Structure and Single Cell Dehydration

The HT-29 control groups and dehydrated cells (20min) were subjected to cryogenic scanning electron microscopy (cryoSEM) analysis. The probes were washed with Dulbecco's phosphate buffered saline (DPBS, Sigma-Aldrich) and fixated in 2.5% glutaraldehyde solution (Sigma-Aldrich). After fixing the samples, they were washed in PBS, rinsed in ultrapure (sterilized through 0.1µm filter) deionized water, and finally mounted on cryo-shuttle using OT/colloid graphite mixture and plunged in liquid nitrogen. Then, frozen specimen were quickly transferred to a cryo-preparation chamber (Cryo Quorum PP3010T) and sputtered with a conductive layer of platinum at 140°C. Next, specimen were transferred to the microscopy chamber. At each point of transfer, the same temperature of -140°C (Auriga60, Zeiss) was maintained. Samples were ultimately observed at 2kV of acceleration voltage using In Lens and SE2 secondary electron detector.

Graphic Design

For the graphics provided, multiple graphic programs were used. These programs included Inkscape 1.0.1,2020, GNU, USA and programs provided by Windows office 2019, Microsoft.

Statistical Analysis

All experiments were executed at least three times. Each well was considered as a single value, according to the classified subgroups. The student t-test was used to compare independent groups. Probability (p) values were considered as follows: *=p<0.05, **=p<0.01, and #=p>0.05, with p-value <0.05 considered to be statistically significant. Data are presented as the mean standard deviation unless otherwise indicated.

RESULTS

Extent of Laparoscopic Intraabdominal Dehydration and Transport Capacity

Under the presented constellation at 15 l/min flow, outflow humidity levels reached > 95% within the first 5 minutes and

stabilized at around 99%. The mean inflow humidity level was 51%. The intraperitoneal temperature remained stable and did not exceed 40°C. Macroscopically visible dehydration set in after 25, 28 and 33 minutes within the procedure (**Figures 2A, B**). The calculation of the maximum transport capacity uncovered that under the presented constellation of high flow *via* the laparoscopic approach, a mean amount of 0.382 grams per minute of water was removed from the peritoneum (**Figure 3A**). This approximated to a total of 17.2 grams of water in 45 minutes (**Figure 3B**). Thus, dehydration set in after the removal of circa 10.7 \pm 1.6 g of water from the abdominal cavity.

In-Vitro Cytotoxicity of Dehydration and Hyperthermia

Cytotoxicity levels were significantly increased following hyperthermia at 45°C (p<0.05) and 48°C (p<0.001) compared to controls at 37°C (**Figure 4A**). Moreover, the combination of hyperthermia and dehydration showed similarly high cytotoxicity levels (**Figure 4B**). After 10 minutes of dehydration, cytotoxicity levels were high for all temperature groups and remained at this elevated level. However, in cells kept at 37°C and only exposed to dehydration, cytotoxicity increased to elevated levels after 10 minutes (**Figure 4C**).

Viability of HT-29 Cells Following Dehydration and Hyperthermia

The viability of HT-29 cells was not affected by hyperthermia at 45°C and 48°C compared to controls at 37°C (**Figure 5A**). However, the combination of hyperthermia at 48°C and dehydration of 30 minutes resulted in significantly decreased viability levels (p<0.01) (**Figure 5B**). Dehydration of cells at 37°C resulted in declined viability with time (0 - 30 minutes). However, this effect seemed to be further enhanced when hyperthermia was added at 45°C and 48°C (**Figure 5C**).

Electron Microscopic Analysis on Dehydrated HT-29 Cells

Cryo-SEM was used to study cell morphology following partial dehydration. Structural analyses of the extracellular cell surface revealed morphological changes which progressed with increased extent of dehydration. Control cells were more distinguishable and separable from each other. Some had a round shape and podocytes were visible for most cells (**Figure 6A**). Their dehydrated counterparts had blurred margins, and the cells appeared hollow and flattened (**Figure 6B**). Cell boundaries were more difficult to identify. Podocyte structures of cells had become visually unidentifiable. EM analyses concluded that dehydration significantly affected the structural integrity of HT-29 cells.

DISCUSSION

The concept of a therapeutic pneumoperitoneum was inspired by Italian physician Carlo Forlanini (1847 - 1918), whose pioneering innovations helped to manage extensive pulmonary tuberculosis following decades of stagnating therapeutic options.





In the early 20th century, he developed the idea of an artificial pneumothorax for patients suffering from pulmonary tuberculosis. This innovative concept benefited severely ill patients, and Forlanini was later nominated for the Nobel prize for medicine for his discovery (24). Based on the consideration that biophysical changes of the thorax and a less hospitable environment for tuberculosis bacteria might have been the reason for the success of this unconventional approach, we theorize that our model of cell dehydration could have similar promising effects on PM. In patients with cancer diseases, the metastatic process in the peritoneal cavity is a critical factor for survival (25). Using physical principles in innovative treatments of

PM and other surface malignancies seems promising and has been attempted several times (26–29). Some of these novel treatment options have been extensively tested, including the application of irradiation (30–32), high-intensity ultrasound (33, 34) and nanoparticles (16). The current management of PM displays significant shortcomings due to the aggressive growth behavior displayed by PM, which further limits effects of i.p. chemotherapy even when locally applied during HIPEC or PIPAC.

Cancer cells within the abdominal cavity usually originate from either gastrointestinal or gynecological cells. Therefore, they are habituated to a fluid-surrounding environment. This aspect remains unchanged, regardless of mutations in the cancer







cell genome (35). Consequently, changing the basic biology of the abdominal cavity might interfere with any cancerous progression in that compartment. Dehydrating the internal cavity accounts for one of these basic biological changes in the human body. With this study, we were able to demonstrate that HT-29 cells subjected to dehydration show reduced viability rates, especially when combined with hyperthermia. Our model has thoroughly demonstrated that dehydration can be implemented in a laparoscopic model established within a reasonable timeframe of less than 45 minutes. With our work, we have outlined a basic conceptual comprehension of the technical and physical aspects as well as applicational limitations of dehydration. This approach needs to be further investigated to evaluate the potential of i.p. dehydration in the management of advanced PM. Dehydration with hyperthermia as a combined application or possibly in addition to chemotherapy, could be a realistic tool for changing the i.p. environment to slow down or even terminate PM progression. Significant reduction of HT-29 cell viability and significantly increased cytotoxicity has been observed following dehydration combined with hyperthermia. Applicational, biological and technical features of dehydration within the peritoneal cavity have been demonstrated and must be further examined and documented. While this new concept operates without any pharmacological agents, it can possibly be combined with some of the current concepts of i.p. chemotherapy (36, 37).

With regards to limitations in this study, we must point out that PM can originate from different cancer entities, including a variety of gastrointestinal or gynecological tumors, and thus may show differing reactions to dehydration. Furthermore, there is still a



FIGURE 5 | (A) *In vitro* cell-viability of colon cancer cells after 30 minutes of hyperthermia (without dehydration) at 45°C and 48°C. Control cells were only exposed to the physiological temperature of 37°C. (B) *In vitro* cell-viability of colon cancer cells after 30 minutes of hyperthermia and dehydration at 37°, 45°C and 48°C. (C) Course of cell viability following different exposure times of dehydration and hyperthermia 0 (Control), 5, 10, 20, 25 and 30 minutes. Significance levels: #=p>0.05,**= p<0.01.



limited understanding and knowledge on potential local and systemic effects of this novel concept. Also, the potential hemodynamic effects of dehydration and hyperthermia must be further evaluated. In the future, clinical studies in selected and qualified research centers are required to further assess this concept and allow for a more in-depth evaluation of its applicability.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by Wroclaw university of life and environmental sciences.

AUTHOR CONTRIBUTIONS

AD: Study design, laboratory analysis, data acquisition, editing. TK: Study design, conception of the study and manuscript drafting. AM-M: Study design, laboratory analysis, data acquisition. JN: Study design, laboratory analysis, data acquisition. ZK: Manuscript drafting and critical revision for important intellectual content of the manuscript. PP: laboratory analysis, data acquisition. BL: Study design, laboratory analysis. WK: Drafting and critical revision for important intellectual content of the manuscript. KZ: laboratory analysis, data acquisition, PM: laboratory analysis, data acquisition. HL: Drafting and critical revision for important intellectual content of the manuscript. SL: Drafting and critical revision for important intellectual content of the manuscript. VK: Supervision on study design, laboratory analyses, conception of the study and manuscript drafting. All authors contributed to the article and approved the submitted version.

FUNDING

This study was funded by institutional funds of the Department of Biochemistry and Molecular Biology, Faculty of Veterinary Sciences, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland and the Department of Surgery, Petrus-Hospital Wuppertal, Wuppertal, Germany.

REFERENCES

- Paul Olson TJ, Pinkerton C, Brasel KJ, Schwarze ML. Palliative Surgery for Malignant Bowel Obstruction From Carcinomatosis: A Systematic Review. *JAMA Surg* (2014) 149(4):383–92. doi: 10.1001/jamasurg.2013.4059
- 2. Heaney RM, Shields C, Mulsow J. Outcome Following Incomplete Surgical Cytoreduction Combined With Intraperitoneal Chemotherapy for Colorectal

Peritoneal Metastases. World J Gastrointest Oncol (2015) 7(12):445-54. doi: 10.4251/wjgo.v7.i12.445

 Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/ Gynecologic Oncology Group Study. J Clin Oncol (2019) 37(16):1380–90. doi: 10.1200/JCO.18.01568

- 4. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer. J Clin Oncol (2003) 21(20):3737–43. doi: 10.1200/ JCO.2003.04.187
- Oseledchyk A, Zivanovic O. Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. Oncol (Williston Park) (2015) 29(9):695–701.
- Rosa F, Galiandro F, Ricci R, Di Miceli D, Quero G, Fiorillo C, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases: Analysis of Short- and Long-Term Outcomes. *Langenbecks Arch Surg* (2021) 406(8):2797–805. doi: 10.1007/s00423-021-02353-z
- Chen WC, Huang HJ, Yang LY, Pan YB, Huang KG, Lin CT, et al. Hyperthermic Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer. *BioMed J* (2021) 137(21):2319–4170. doi: 10.1016/ j.bj.2021.10.003
- Parikh MS, Johnson P, Romanes JP, Freitag HE, Spring ME, Garcia-Henriquez N, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review. *Dis Colon Rectum* (2022) 65(1):16–26. doi: 10.1097/ DCR.000000000002315
- Carboni F, Federici O, Zazza S, Corona F, Massimi F, Sperduti I, et al. Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis of non-Primary Origin. *Langenbecks Arch Surg* (2021) 406(8):2817–25. doi: 10.1007/s00423-021-02354-y
- Khosrawipour T, Schubert J, Khosrawipour V, Chaudhry H, Grzesiak J, Arafkas M, et al. Particle Stability and Structure on the Peritoneal Surface in Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) Analysed by Electron Microscopy: First Evidence of a New Physical Concept for PIPAC. Oncol Lett (2019) 17(6):4921–7. doi: 10.3892/ol.2019.10162
- Mikolajczyk A, Khosrawipour V, Schubert J, Chaudhry H, Pigazzi A, Khosrawipour T. Particle Stability During Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC). *Anticancer Res* (2018) 38(8):4645–9. doi: 10.21873/anticanres.12769
- Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized Intra Peritoneal Aerosol Chemotherapy in Patients Suffering From Peritoneal Carcinomatosis of Pancreatic Adenocarcinoma. *PLoS One* (2017) 12(10): e0186709. doi: 10.1371/journal.pone.0186709
- Schubert J, Khosrawipour V, Chaudhry H, Arafkas M, Knoefel WT, Pigazzi A, et al. Comparing the Cytotoxicity of Taurolidine, Mitomycin C, and Oxaliplatin on the Proliferation of *In Vitro* Colon Carcinoma Cells Following Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC). *World J Surg Oncol* (2019) 17(1):93. doi: 10.1186/s12957-019-1633-5
- Khosrawipour V, Reinhard S, Martino A, Khosrawipour T, Arafkas M, Mikolajczyk A. Increased Tissue Penetration of Doxorubicin in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) After High-Intensity Ultrasound (HIUS). Int J Surg Oncol (2019) 2019:6185313. doi: 10.1155/2019/6185313
- Mikolajczyk A, Khosrawipour V, Kulas J, Kocielek K, Migdal P, Arafkas M, et al. Release of Doxorubicin From its Liposomal Coating *via* High Intensity Ultrasound. *Mol Clin Oncol* (2019) 11(5):483–7. doi: 10.3892/mco.2019.1917
- 16. Khosrawipour T, Schubert J, Kulas J, Migdal P, Arafkas M, Bania J, et al. Creating Nanocrystallized Chemotherapy: The Differences in Pressurized Aerosol Chemotherapy (PAC) via Intracavitary (IAG) and Extracavitary Aerosol Generation (EAG) Regarding Particle Generation, Morphology and Structure. J Cancer (2020) 11(6):1308–14. doi: 10.7150/jca.39097
- van Baal JOAM, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ, et al. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. J Histochem Cytochem (2018) 66(2):67–83. doi: 10.1369/0022155417742897
- Lemoine L, Sugarbaker P, van der Speeten K. Pathophysiology of Colorectal Peritoneal Carcinomatosis: Role of the Peritoneum. World J Gastroenterol (2016) 22(34):7692–707. doi: 10.3748/wjg.v22.i34.7692
- Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL. Principles and Methods of Integrative Genomic Analyses in Cancer. *Nat Rev Cancer* (2014) 14(5):299–313. doi: 10.1038/nrc3721

- Chin L, Andersen JN, Futreal PA. Cancer Genomics: From Discovery Science to Personalized Medicine. *Nat Med* (2011) 17(3):297–303. doi: 10.1038/ nm.2323
- Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, et al. Cancer Genomics: Technology, Discovery, and Translation. *J Clin Oncol* (2012) 30(6):647–60. doi: 10.1200/JCO.2011.39.2316
- 22. Jayne D. Molecular Biology of Peritoneal Carcinomatosis. *Cancer Treat Res* (2007) 134:21–33. doi: 10.1007/978-0-387-48993-3_2
- Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-Cell and Cell-Matrix Dynamics in Intraperitoneal Cancer Metastasis. *Cancer Metastasis Rev* (2012) 31(1-2):397–3414. doi: 10.1007/s10555-012-9351-2
- Hansson N, Polianski IJ. Therapeutic Pneumothorax and the Nobel Prize. *Ann Thorac Surg* (2015) 100(2):761–5. doi: 10.1016/j.athoracsur.2015.03.100
- Kim YJ, Kim CH. Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer. Ann Coloproctol (2021) 37(6):425–33. doi: 10.3393/ ac.2021.00920.0131
- 26. Göhler D, Große S, Bellendorf A, Falkenstein TA, Ouaissi M, Zieren J, et al. Hyperthermic Intracavitary Nanoaerosol Therapy (HINAT) as an Improved Approach for Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC): Technical Description, Experimental Validation and First Proof of Concept. *Beilstein J Nanotechnol* (2017) 8:2729–40. doi: 10.3762/bjnano.8.272
- Schubert J, Khosrawipour T, Reinhard S, Arafkas M, Martino A, Bania J, et al. The Concept of Foam as a Drug Carrier for Intraperitoneal Chemotherapy, Feasibility, Cytotoxicity and Characteristics. *Sci Rep* (2020) 10(1):10341. doi: 10.1038/s41598-020-67236-7
- Mikolajczyk A, Khosrawipour V, Schubert J, Plociennik M, Nowak K, Fahr C, et al. Feasibility and Characteristics of Pressurized Aerosol Chemotherapy (PAC) in the Bladder as a Therapeutical Option in Early-Stage Urinary Bladder Cancer. *In Vivo* (2018) 32(6):1369–72. doi: 10.21873/ invivo.11388
- Khosrawipour V, Mikolajczyk A, Paslawski R, Plociennik M, Nowas K, Kulas J, et al. Intrathoracic Aerosol Chemotherapy via Spray-Catheter. Mol Clin Oncol (2020) 12(4):350–4. doi: 10.3892/mco.2020.1999
- 30. Khosrawipour V, Khosrawipour T, Hedayat-Pour Y, Diaz-Carballo D, Bellendorf A, Böse-Ribeiro H, et al. Effect of Whole-Abdominal Irradiation on Penetration Depth of Doxorubicin in Normal Tissue After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a Post-Mortem Swine Model. *Anticancer Res* (2017) 37(4):1677–80. doi: 10.21873/anticanres.11498
- Khosrawipour V, Giger-Pabst U, Khosrawipour T, Pour YH, Diaz-Carballo D, Förster E, et al. Effect of Irradiation on Tissue Penetration Depth of Doxorubicin After Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a Novel *Ex-Vivo* Model. J Cancer (2016) 7(8):910–4. doi: 10.7150/jca.14714
- 32. Khosrawipour V, Bellendorf A, Khosrawipour C, Hedayat-Pour Y, Diaz-Carballo D, Förster E, et al. Irradiation Does Not Increase the Penetration Depth of Doxorubicin in Normal Tissue After Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. In Vivo (2016) 30 (5):593–7.
- 33. Lau H, Khosrawipour T, Mikolajczyk A, Frelkiewicz P, Nicpon J, Arafkas M, et al. Intraperitoneal Chemotherapy of the Peritoneal Surface Using High-Intensity Ultrasound (HIUS): Investigation of Technical Feasibility, Safety and Possible Limitations. J Cancer (2020) 11(24):7209–15. doi: 10.7150/ jca.48519
- 34. Mikolajczyk A, Khosrawipour T, Kulas J, Migdal P, Arafkas M, Nicpon J, et al. The Structural Effect of High Intensity Ultrasound on Peritoneal Tissue: A Potential Vehicle for Targeting Peritoneal Metastases. *BMC Cancer* (2020) 20 (1):481. doi: 10.1186/s12885-020-06981-4
- Karunasena E, Sham J, McMahon KW, Ahuja N. Genomics of Peritoneal Malignancies. Surg Oncol Clin N Am (2018) 27(3):463–75. doi: 10.1016/ j.soc.2018.02.004
- Mikolajczyk A, Khosrawipour V, Schubert J, Grzesiak J, Chaudhry H, Pigazzi A, et al. Effect of Liposomal Doxorubicin in Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC). J Cancer (2018) 9(23):4301–5. doi: 10.7150/ jca.26860
- 37. Khosrawipour V, Mikolajczyk A, Schubert J, Khosrawipour T. Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) via Endoscopical

Microcatheter System. Anticancer Res (2018) 38(6):3447-52. doi: 10.21873/anticanres.12613

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Diakun, Khosrawipour, Mikolajczyk-Martinez, Nicpoń, Kielbowicz, Prządka, Liszka, Kielan, Zielinski, Migdal, Lau, Li and Khosrawipour. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.